Coherus Biosciences

Coherus BioSciences reported Q1 2026 revenue of $12.31 million, missing the $14.43 million estimate, while EPS of -$0.25 matched expectations. Despite the revenue shortfall, the stock rose 11.43% in after-hours trading to $1.89, driven by optimism about growth opportunities and strategic initiatives. Lead product LOQTORZI achieved 61% year‑over‑year revenue growth; management expects a weather‑related recovery in Q2 and targets quarterly revenues of $15 million by the end of 2026 and $30–35 million for 2027. » More on de.investing.com

Under CEO Dennis Lanfear, Coherus BioSciences is making a strategic shift to oncology with an emphasis on immune resistance and is strengthening its pipeline through the acquisition of Surface Oncology and the sale of biosimilar assets. The sale proceeds from UDENYCA generated an upfront payment of $483 million plus expected follow‑on payments, and the company raised an additional $50 million. LOQTORZI revenue rose to $40.8 million in 2025 and is expected to cover sales expenses by 2026 and core operating costs by 2027; clinical data on Tagmokitug and Casdozokitug are considered promising. Coherus is expanding its sales force, pursuing partnerships outside the U.S., and is targeting a mid‑term market share of 70% for LOQTORZI. » More on de.investing.com

At the TD Cowen conference Coherus BioSciences announced a strategic realignment toward oncology, highlighted its improved financial position and the development of an innovative pipeline. The company reduced debt from $480 million to $3.7 million, received $250 million from the sale of its biosimilar business and reported LOQTORZI revenues of $38 million (2025); it is targeting a $175 million run rate by 2028. Coherus aims for cash‑flow breakeven at about $30 million in quarterly LOQTORZI sales, plans partnerships for Tagmokitug and Casdozokitug, and expects initial phase‑2 data for Casdozokitug midyear with a reported complete response rate of 17% in liver cancer. » More on de.investing.com